Rawashdeh Mazen 4
4 · EBAY INC · Filed May 27, 2026
Research Summary
AI-generated summary of this filing
eBay (EBAY) CTO Mazen Rawashdeh Sells Shares After Option Exercises
What Happened
Mazen Rawashdeh, Senior Vice President and Chief Technology Officer at eBay, exercised option-related shares and sold 50,000 eBay shares in multiple open-market trades on May 22, 2026. The sales totaled approximately $5,852,072 across four trades (14,058; 17,179; 18,663; 100 shares) at prices ranging roughly from $115.60 to $118.61. The filing also reports exercise/conversion entries for two 50,000-share derivative transactions (M-code entries). The exercises and sales were executed pursuant to a pre-established Rule 10b5‑1 trading plan adopted February 20, 2026.
Key Details
- Transaction date: May 22, 2026; Form 4 filed May 27, 2026 (appears filed late vs. the typical 2-business-day deadline).
- Open-market sale totals: 50,000 shares sold for ~$5,852,072. Reported per-trade proceeds: $1,630,587; $2,009,256; $2,200,368; $11,861.
- Sale price ranges / weighted averages: trades covered prices from $115.60–$118.61 (footnotes F3–F5 provide weighted-average ranges and note detailed price breakdowns available upon request).
- Derivative/exercise entries: two M-code entries for 50,000 shares each (one reported as acquired, one as a derivative disposition) — filing indicates option/award vesting schedule (F6) with full vesting completed on 3/15/2026.
- 10b5‑1 plan: both the exercises and the sales were made pursuant to a Rule 10b5‑1 trading plan adopted Feb 20, 2026 (footnotes F1–F2).
- Shares owned after transaction: not specified in the provided summary of the filing. The filing does note an additional 302 shares acquired under eBay’s Employee Stock Purchase Plan on April 30, 2026 (included in Table I, Column 5).
Context
This was an exercise of option-derived shares followed by open-market sales under a pre-established 10b5‑1 plan. The $0.00 per-share amount shown for the exercise entries typically reflects reporting conventions for exercised derivatives (e.g., net-share settlement or non-cash conversion) rather than a market purchase at zero price; the filing’s footnotes and vesting schedule explain the award background. Sales under 10b5‑1 plans are generally routine and scheduled trades; they should not be taken alone as a signal of management sentiment.
Insider Transaction Report
- Exercise/Conversion
Common Stock
[F1]2026-05-22+50,000→ 79,217 total - Sale
Common Stock
[F2][F3]2026-05-22$115.99/sh−14,058$1,630,587→ 65,159 total - Sale
Common Stock
[F2][F4]2026-05-22$116.96/sh−17,179$2,009,256→ 47,980 total - Sale
Common Stock
[F2][F5]2026-05-22$117.90/sh−18,663$2,200,368→ 29,317 total - Sale
Common Stock
[F2]2026-05-22$118.61/sh−100$11,861→ 29,217 total - Exercise/Conversion
Non-Qualified Stock Option (Right to Buy) - 2
[F1][F6]2026-05-22−50,000→ 123,829 totalExercise: $44.37Exp: 2033-04-01→ Common Stock (50,000 underlying)
Footnotes (6)
- [F1]The shares were exercised pursuant to a Rule 10b-5 trading plan adopted by the Reporting Person on February 20, 2026.
- [F2]The shares were sold pursuant to a Rule 10b-5 trading plan adopted by the Reporting Person on February 20, 2026.
- [F3]Represents the weighted average price of shares sold at prices that ranged from $115.60 to $116.52. The reporting person hereby undertakes to provide upon request to the SEC staff, the issuer or a security holder of the issuer full information regarding the number of shares sold at each separate price.
- [F4]Represents the weighted average price of shares sold at prices that ranged from $116.61 to $117.60. The reporting person hereby undertakes to provide upon request to the SEC staff, the issuer or a security holder of the issuer full information regarding the number of shares sold at each separate price.
- [F5]Represents the weighted average price of shares sold at prices that ranged from $117.61 to $118.58. The reporting person hereby undertakes to provide upon request to the SEC staff, the issuer or a security holder of the issuer full information regarding the number of shares sold at each separate price.
- [F6]On 3/15/2024, 28,972 of the options granted under this award vested and became exercisable, on 3/15/2025, 86,916 of the options granted under this award vested and became exercisable, and on 3/15/2026, the remaining 57,941 of the options granted under this award vested and became exercisable, each as a result of time and performance based vesting.